3-[(4-fluoro-2-nitrophenyl)amino]propanenitrile | 328546-72-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(4-fluoro-2-nitrophenyl)amino]propanenitrile
• 英文别名: 3-(4-fluoro-2-nitro-phenylamino)-propionitrile；3-(4-fluoro-2-nitroanilino)propanenitrile
• CAS: 328546-72-1
• 化学式: C₉H₈FN₃O₂
• 分子量: 209.18
• InChiKey: FMLBWKVCXIVSAX-UHFFFAOYSA-N

物化性质

• 沸点：
  412.8±45.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  81.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-[(4-fluoro-2-nitrophenyl)amino]propanenitrile 在 盐酸 、 palladium on activated charcoal 、 氢气 、 sodium ethanolate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 ethyl 7-fluoro-1,2-dihydro-3-oxopyrido[1,2-a]benzimidazole-4-carboxylate
  参考文献：
  名称：

  Process Research for the Synthesis of RWJ-51204, A Novel Anxiolytic Agent

  摘要：

  RWJ-51204, the lead compound in our pyrido [1,2-a] benzimidazole (PBI) series, was shown to exhibit anxiolytic efficacy in animal models at doses which did not cause central nervous system side effects commonly observed with other anxiolytic agents. To prepare supplies of drug substance for early toxicological and clinical studies, we needed to develop a safe and scaleable synthesis, Our main focus was to improve the last two steps of the process which involved formation of the penultimate carboxamide intermediate followed by alkylation using potentially toxic chloromethyl ethyl ether. Due to safety issues concerning storage and handling of this reagent during the large scale synthesis, we investigated alternate routes to minimize potential exposure risks. The process research carried out for the final steps that led to the safe and cost-effective multi-kilogram synthesis of RWJ-51204 is described herein.

  DOI：

  10.1021/op990182l
• 作为产物：
  描述：

  4-氟-2-硝基苯胺 以93的产率得到3-[(4-fluoro-2-nitrophenyl)amino]propanenitrile
  参考文献：
  名称：

  S-heteroatom containing alkyl

  摘要：

  公式为1；##STR1## 的化合物被披露为有用的治疗中枢神经系统疾病。还披露了药物组成和治疗方法。

  公开号：

  US05817668A1

文献信息

• Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
  申请人：Isaac Methvin

  公开号：US20070032469A1

  公开（公告）日：2007-02-08

  The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 3 , A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.

  该发明提供了一个式(I)的化合物或其药用盐：其中R1、R2、R3、A、B、D、m、n、x和y的定义如规范中所述。该发明还提供了一种包含式I化合物的药用组合物，以及使用该组合物来治疗或预防神经学和精神疾病的方法。这些化合物在与mGluR2受体介导的疾病的治疗或预防相关的治疗中是有用的。
• [EN] 4,5-DIHYDRO-IMIDAZO[4,5,1-II]QUINOLIN-6-ONES AS PARP INHIBITORS<br/>[FR] 4,5-DIHYDRO-IMIDAZO(4,5,1-IJ)QUINOLIN-6-ONES UTILISEES COMME INHIBITEURS DE PARP
  申请人：ALTANA PHARMA AG

  公开号：WO2004108723A1

  公开（公告）日：2004-12-16

  Compounds of the formula 1, in which R1 and R2 have the meanings indicated in the description, are novel active PARP inhibitors.

  式1中，其中R1和R2具有描述中指示的含义的化合物是新颖的活性PARP抑制剂。
• Tricyclic inhibitors of poly(ADP-ribose) polymerases
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06548494B1

  公开（公告）日：2003-04-15

  Compounds of the formula shown below are poly(ADP-ribosyl)transferase inhibitors: Such compounds are useful as therapeutics in treating cancers and in ameliorating the effects of stroke, head trauma, and neurodegenerative disease.

  以下化学式显示的化合物是聚(ADP-核糖基)转移酶抑制剂：这些化合物在治疗癌症和改善中风、头部创伤和神经退行性疾病的疗效方面非常有用。
• Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
  申请人：Isaac Methvin

  公开号：US20080318999A1

  公开（公告）日：2008-12-25

  The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 3 , A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.

  该发明提供了式（I）的化合物或其药学上可接受的盐：其中，R1、R2、R3、A、B、D、m、n、x和y的定义如规范所述。此外，该发明还提供了包括式I的药学组合物，以及使用该组合物治疗或预防神经系统和精神疾病的方法。这些化合物在治疗或预防mGluR2受体介导的疾病的相关治疗中是有用的。
• Org. Process Res. Dev. 1999, 3, 260-265
  作者：

  DOI：——

  日期：——